NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced that it has discontinued treatment of all enrolled patients participating in the 40 mg cohort of its Phase II dose-finding study of incyclinide for the treatment of acne.
From: biz.yahoo.com
CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of ...
Posted by Ruslan Abuzant at 6:38 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment